Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Driggin, Mahesh Madhavan, B. Bikdeli, Taylor Chuich, Justin Laracy, G. Biondi‐Zoccai, Tyler Brown, Caroline Nigoghossian, David Zidar, J. Haythe, D. Brodie, J. Beckman, A. Kirtane, G. Stone, H. Krumholz, S. Parikh (2020)
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 PandemicJournal of the American College of Cardiology, 75
Savalan Babapoor-Farrokhran, Deanna Gill, J. Walker, Roozbeh Rasekhi, Behnam Bozorgnia, A. Amanullah (2020)
Myocardial injury and COVID-19: Possible mechanismsLife Sciences, 253
(2020)
Is it the virus, hyperinflammation, or MODS? SARS-CoV-2 als mögliche Ursache für Myokarditis und Herzinsuffizienz. Ist es das Virus, Hyperinflammation oder MODS?
K. Clerkin, J. Fried, J. Raikhelkar, G. Sayer, J. Griffin, A. Masoumi, Sneha Jain, D. Burkhoff, Deepa Kumaraiah, L. Rabbani, A. Schwartz, N. Uriel (2020)
COVID-19 and Cardiovascular Disease, 141
T. Xiong, S. Redwood, B. Prendergast, Mao Chen (2020)
Coronaviruses and the cardiovascular system: acute and long-term implicationsEuropean Heart Journal, 41
B. Maisch (2020)
SARS-CoV-2 as potential cause of cardiac inflammation and heart failure. Is it the virus, hyperinflammation, or MODS?Herz, 45
A. Kochi, A. Tagliari, G. Forleo, G. Fassini, C. Tondo (2020)
Cardiac and arrhythmic complications in patients with COVID‐19Journal of Cardiovascular Electrophysiology, 31
G. Lippi, C. Lavie, F. Sanchis-Gomar (2020)
Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis☆Progress in Cardiovascular Diseases, 63
Chaolin Huang, Ye-ming Wang, Xing-wang Li, L. Ren, Jianping Zhao, Y. Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu, Zhenshun Cheng, Ting Yu, Jia’an Xia, Yuan Wei, Wenjuan Wu, Xuelei Xie, Wen Yin, Hui Li, Min Liu, Yan Xiao, Hong Gao, Li Guo, Jungang Xie, Guangfa Wang, R. Jiang, Zhancheng Gao, Q. Jin, Jianwei Wang, B. Cao (2020)
[Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control].Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 41 12
G. Oudit, Z. Kassiri, C. Jiang, Peter Liu, S. Poutanen, J. Penninger, J. Butany (2009)
SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARSEuropean Journal of Clinical Investigation, 39
Liang Chen, Xiangjie Li, Mingquan Chen, Yi Feng, C. Xiong (2020)
The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2Cardiovascular Research
T. Guzik, S. Mohiddin, A. Dimarco, V. Patel, K. Savvatis, F. Marelli-Berg, M. Madhur, M. Tomaszewski, P. Maffia, F. D’Acquisto, S. Nicklin, A. Marian, R. Nosalski, E. Murray, B. Guzik, C. Berry, R. Touyz, R. Kreutz, Daowen Wang, D. Bhella, Orlando Sagliocco, F. Crea, E. Thomson, I. McInnes (2020)
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment optionsCardiovascular Research, 116
Hongde Hu, Fenglian Ma, Xin Wei, Yuan Fang (2020)
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulinEuropean Heart Journal, 42
Indranill Basu-Ray, M. Soos (2020)
Cardiac Manifestations Of Coronavirus (COVID-19)
J. Augoustides (2020)
Cardiovascular Consequences and Considerations of Coronavirus Infection – Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus CrisisJournal of Cardiothoracic and Vascular Anesthesia, 34
J. Hulot (2020)
COVID-19 in patients with cardiovascular diseasesArchives of Cardiovascular Diseases, 113
Zhe Xu, Lei Shi, Yijin Wang, Jiyuan Zhang, Lei Huang, Chao Zhang, Shuhong Liu, Peng Zhao, Hongxia Liu, Li Zhu, Y. Tai, Changqing Bai, T. Gao, Jinwen Song, P. Xia, Jinghui Dong, Jingmin Zhao, Fu-Sheng Wang (2020)
Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet. Respiratory Medicine, 8
Chen Chen, Yiwu Zhou, Daowen Wang (2020)
SARS-CoV-2: a potential novel etiology of fulminant myocarditisHerz, 45
D. Atri, H. Siddiqi, Joshua Lang, V. Nauffal, D. Morrow, E. Bohula (2020)
COVID-19 for the CardiologistJACC: Basic to Translational Science, 5
Qing Deng, Bo Hu, Yao Zhang, Hao Wang, Xiaoyang Zhou, Wei Hu, Yuting Cheng, Jie Yan, H. Ping, Qing Zhou (2020)
Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China☆International Journal of Cardiology, 311
Han Zhu, J. Rhee, Paul Cheng, S. Waliany, A. Chang, R. Witteles, H. Maecker, Mark Davis, P. Nguyen, Sean Wu (2020)
Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune ResponseCurrent Cardiology Reports, 22
M. Bansal (2020)
Cardiovascular disease and COVID-19Diabetes & Metabolic Syndrome, 14
Ying-Ying Zheng, Yi-tong Ma, Jin-Ying Zhang, Xiang Xie (2020)
COVID-19 and the cardiovascular systemNature Reviews. Cardiology, 17
K. Ozierański, A. Tymińska, A. Caforio (2020)
Clinically suspected myocarditis in the course of coronavirus infectionEuropean Heart Journal
S. Sala, G. Peretto, M. Gramegna, A. Palmisano, A. Villatore, D. Vignale, F. Cobelli, M. Tresoldi, A. Cappelletti, C. Basso, C. Godino, A. Esposito (2020)
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infectionEuropean Heart Journal
AbstractMyocarditis is one of the relatively common complications of respiratory infection with SARSCoV-2. As several patients confirmed with the new SARS-CoV-2 are known with cardiovascular disease (CVD) and data from the literature show negative prognosis and a higher risk of complications, this subgroup of subjects represents a particular situation. Therefore, an adequate understanding of the mechanisms involved in myocardial injury and interaction between COVID-19 and CVD is essential for optimal further management. Studies have proved that in COVID-19 patient myocarditis is determined via three pathological mechanisms of cardiomyocyte injury: direct viral cell entry and binding to ACE2, vasculitis-mediated injury, and systemic inflammatory response leading to pro-inflammatory cytokine discharge. Studies show that the incidence of myocarditis in patients with SARS-CoV-2 is relatively low, 4.8%, but myocardial damage occurs in more than 25% of critical cases in the form of acute fulminant myocarditis with severe hemodynamic degradation, or develops when the severity of SARS-CoV-2 infection intensifies. The mortality rate in myocarditis from COVID-19 infection ranges between 50–70%, with poorer prognosis and a higher risk of complications in CVD patients. As in all of these cases increased troponin and natriuretic peptide levels proved to be a negative prognostic factor, for risk stratification and prompt treatment, cardiac biomarkers should be evaluated in all patients with COVID-19.
Journal of Interdisciplinary Medicine – de Gruyter
Published: Sep 1, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.